Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.

Tuberculosis Research Units (U19 Clinical Trial Optional), expires: 09/29/2020

Funding Opportunity Purpose: The purpose of this FOA is to support the establishment of multidisciplinary Tuberculosis (TB) Research Units (TBRUs) that will operate as a collaborative network to improve understanding of Mycobacterium tuberculosis (Mtb)-host interactions through characterization of bacterial and host determinants that are relevant during stages of infection and disease, and analyses of bacterial and host heterogeneity on disease outcomes. 

Application Due Date(s): September 28, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-020.html

Long Acting Treatments for HIV and HIV-Associated Co-Infections (R61/R33 Clinical Trial Not Allowed), expires: 07/29/2020

Funding Opportunity Purpose: The purpose of this Funding Opportunity is to stimulate new and innovative multidisciplinary research in the area of long acting therapeutics for HIV and HIV-associated tuberculosis (TB) and viral hepatitis B and C. Applications are sought that lead to new effective therapies for administration once per month or less frequently as oral, injectable, implantable, or transdermal products.

Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

AIDS Application Due Date(s): July 28, 2020

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-024.html

 

Advancing Vaccine Science to Improve Tuberculosis Treatment Outcomes for People Living With or Without HIV (R01 Clinical Trial Not Allowed), expires: 07/29/2020

Funding Opportunity Purpose: the purpose of this Funding Opportunity Announcement is to invite applications for innovative clinical, and preclinical/translational research to develop therapeutic vaccine strategies to improve treatment outcomes of active tuberculosis (TB) in the presence or absence of HIV co-infection.

Application Due Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.

AIDS Application Due Date(s): July 28, 2020.

All applications are due by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on the listed date(s).

https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-010.html

 

International Research in Infectious Diseases, including AIDS (R01), expires: 08/20/2022

Application Due Date(s): July 15, 2020; July 15, 2021; July 15 2022, by 5:00 PM local time of applicant organization.
AIDS Application Due Date(s): August 19, 2020; August 19, 2021; August 19, 2022, by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) encourages applications from organizations/institutions in eligible foreign countries that propose research related to infectious diseases that are of interest/importance to that country.

https://grants.nih.gov/grants/guide/pa-files/PAR-20-108.html

Develop, Implement, and Evaluate Evidence-based, Innovative Approaches to Prevent, Find, and Cure Tuberculosis in High-Burden Settings, due: 03/03/2020

Deadline: Mar 03, 2020  Electronically submitted applications must be submitted no later than 5:00 p.m., ET, on the listed application due date.

https://www.grants.gov/web/grants/search-grants.html?keywords=RFA-GH-20-001

Funding Opportunity Number: RFA-GH-20-001

Agency Name: Centers for Disease Control and Prevention - ERA

Description:

The End TB Strategy envisions a world free of tuberculosis (TB)—zero deaths, disease and suffering due to TB by 2035. This requires reducing the global TB incidence from >1250 cases per million people to <100 cases per million people within the next two decades. Each year, an estimated 10 million people develop TB disease, and an estimated 1.6 million TB people die from TB – the leading cause of death from any infectious disease. In 2017, 90% of all estimated new TB cases were adults (15 years of age or older), and 9% were persons living with HIV (PLHIV) with 72% living in Africa. Despite being preventable and treatable, large gaps in detection and treatment of TB cases remain; of the estimated 10 million new TB cases in 2017, only 6.4 million TB cases were officially reported. Drug-resistant TB is on the raise, posing significant programmatic challenges. Worldwide, an estimated 580,000 multi-drug-resistant (MDR) TB cases emerge annually. Unfortunately, there are substantial gaps in MDR TB detection and treatment. Approximately 1 of 5 persons needing MDR TB treatment actually receive it, and among those who do receive treatment, less than half (48%) who start treatment finish successfully. These rates are driven by treatment failure, loss to follow-up, and premature death. Globally, it is estimated that 1.7 billion people (about one fourth of the world’s population) are infected with TB and form the next generation of future TB cases. Expanding testing and treatment of TB infection is critical to achieving our elimination goals. However, in high-burden countries, the implementation of tuberculosis preventive treatment (TPT) remains a low priority. The purpose of this NOFO is to develop, implement, and evaluate evidence-based, innovative approaches in collaboration with CDC to: prevent TB infection, disrupt TB transmission, and halt progression of TB disease in high-burden settings; find TB infection and TB disease in all populations, including those most vulnerable (i.e., children, displaced persons, healthcare workers, economically disadvantaged, PLHIV, persons with other co-morbid conditions [alcohol use disorders, diabetes mellitus, persons who use illicit substances, undernourished] and elderly) optimize treatment for TB infection, TB disease, TB/HIV, and MDR TB through new treatment and adherence modalities; improve the use of routinely collected data to monitor and evaluate TB program performance; promote operations research (i.e., local solutions for local problems) for broader application, adoption, and integration into routine TB care and treatment practice.

CRDF: 2019 RePORT South Africa, due 03/02/2020

This announcement invites application(s) from South African investigators working in partnership with one or more U.S.-based investigators to submit research proposals for the establishment of the RePORT SA network, as outlined in this announcement. The aim of this RFP is to create a single network consisting of multiple clinical and laboratory research sites and a multidisciplinary team of investigators that addresses an array of TB research questions of importance to South Africa in the global context. 

This announcement will fund one application for the duration of three years that consists of the following components: 

  • A multidisciplinary research team with appropriate leadership structure that will coordinate and oversee the science of the RePORT SA Network and administrate the logistical needs of the network and its affiliated clinical research sites.
  • Clinical research sites that will implement a network wide prospective observational cohort(s) based on the framework of the RePORT Common Protocol and associated standards.
  • An array of research studies based on the above cohort(s) and/or clinical data and specimens collected (or previously collected) in the cohort(s). 

All proposals must be submitted electronically through CRDF Global’s Electronic Proposal Submission (EPS) website, no later than March 2nd, 2020 (23:59) U.S. Standard Time (EST).

https://www.crdfglobal.org/funding-opportunities/2019-report-south-africa

RePORT International Coordinating Center, due 12/02/19

CRDF Global is accepting proposals on behalf of the Division of AIDS (DAIDS) at the National Institute of Allergy and Infectious Diseases (NIAID) to form the 2020 RePORT International Coordinating Center (RICC) to support the planning and implementation of clinical research across the RePORT consortia that addresses the scientific priorities of RePORT and supports coordination of these activities.

The RICC will facilitate collaborative research between the existing RePORT networks through the establishment of a representative Leadership Group (LG), an administrative core, and implementation of a research project(s) of joint priority to the member networks.

The purpose of the RICC is to:

▪ Advance collaborative TB science, which is relevant in a global, international context, especially research of relevance to TB-HIV affected populations.

▪ Serve as an entity to foster research collaboration internationally, with the aim of carrying out a wide range of basic and clinical research that can lead to clinically important biomarkers, vaccines, drugs, and diagnostics.

▪ Curate and advance data, specimen, and other research standards to facilitate collaborative research among RePORT affiliated researchers and institutions, including the Common Protocol.

Eligible applicants must be Principal Investigators of actively funded RePORT International participating sites/networks within the RePORT International consortium.

All proposals must be submitted electronically through CRDF Global’s Electronic Proposal Submission (EPS) website, no later than December 2, 2019 (23:59) U.S. Standard Time (EST). The website will be available on November 1, 2019.

 

https://www.crdfglobal.org/funding-opportunities/2020-RePORT-International-RICC 

Licensing Opportunity: Improved Antibiotic Therapy of Mycobacterium Tuberculosis

Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection

This invention describes the adjunctive use of heme oxygenase-1 (HO-1) inhibitors to improve the outcome of conventional antibiotic treatment for tuberculosis. The existent standard of care requires prolonged administration of drug. Due to the long duration of treatment, methods that can more rapidly control tuberculosis in patients are clearly needed.

NIAID researchers have discovered that inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control. In particular, it was found using a mouse model that HO-1 inhibitors enhance bacterial clearance when used in conjunction with conventional antibiotic therapy. Further, no obvious toxic side effects were found. Since this host-directed strategy does not directly target the pathogen itself, it may have an added advantage as a treatment for infections with antibiotic-resistant Mtb strains.

Licensing Contact:
James Robinson,
Email: james.robinson4@nih.gov
Phone: 301-761-7542

More information: https://www.ott.nih.gov/technology/e-174-2016

Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01/R21), expires 01/08/2022

Due Dates: January 8, 2020; January 8, 2021; January 10, 2022

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.

R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-357.html

R21: https://grants.nih.gov/grants/guide/pa-files/par-19-364.html